Biotech company Alnylam, which focuses on gene silencing (RNAi) technology, has unveiled an ambitious five-year growth plan. The aim is to reassure investors in a situation where sales of its key drugs have fallen short of initial expectations. The plan is intended to cover a period of five years and includes goals in the area of development of the drug portfolio and financial performance. The company communicates that it wants to continue to expand its RNAi-based drug offering despite weaker current sales. As part of the strategy, Alnylam is trying to strengthen its position among the leading biotechnology companies. The company addresses a message to investors to continue to trust it based on this long-term plan. The article highlights the tension between the company's ambitious goals and the reality of lower sales from core products.